𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A year's experience of L-DOPA in the treatment of Parkinson's disease

✍ Scribed by B. Guidetti; R. Giuffrè

Publisher
Springer Vienna
Year
1971
Tongue
English
Weight
376 KB
Volume
24
Category
Article
ISSN
0001-6268

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dementia and treatment with L-dopa in Pa
Dementia and treatment with L-dopa in Parkinson's disease
✍ M. Hietanen; Dr. H. Teräväinen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L-dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who w

Focusing effects of L-dopa in Parkinson'
Focusing effects of L-dopa in Parkinson's disease
✍ Bernard Ng; Samantha Palmer; Rafeef Abugharbieh; Martin J. McKeown 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB

## Abstract Previous fMRI motor studies in Parkinson's disease (PD) have suggested that L‐dopa may “normalize” areas of hypo‐ and hyperactivity. However, results from these studies, which were largely based on analyzing BOLD signal amplitude, have been conflicting. Examining only amplitude changes

Comparative study of selegiline plus L-d
Comparative study of selegiline plus L-dopa–carbidopa versus L-dopa–carbidopa alone in the treatment of parkinson's disease
✍ Timothy Brannan; Dr. Melvin D. Yahr 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 1 views

The long-term effect of selegiline (L-deprenyl) in the treatment of Parkinson's disease has not been clearly delineated. We report on a group of patients whose treatment was initiated with selegiline (n = 43) and then subsequently included L-dopa-carbidopa (Sinemet) and in whom an extended period o